Literature DB >> 22330340

Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.

Lihua Li1, Aaron L Sarver, Setara Alamgir, Subbaya Subramanian.   

Abstract

Elevated levels of PAX3 and cell proliferation genes are characteristic features of rhabdomyosarcoma (RMS). We hypothesize that the increased levels of these genes are stabilized due to downregulation of specific miRNAs. In this study, we show that downregulation of miR-1, -206 and -29 stabilizes the expression of PAX3 and CCND2 in both embryonal (ERMS) and alveolar (ARMS) RMS types. Ectopic expression of miR-1 and 206 in JR1, an ERMS cell line, show significant downregulation of PAX3 protein expression, whereas overexpression of these miRNAs in Rh30, an ARMS cell line, did not show any effect in PAX3 protein levels. In ARMS, PAX3 forms a fusion transcript with FOXO1 and the resultant loss of PAX3 3'UTR in the fusion transcript indicate an oncogenic mechanism to evade miRNA-mediated regulation of PAX3. Further, we show that miR-1, -206 and -29 can regulate the expression of CCND2, a cell cycle gene. In addition to CCND2, miR-29 also targets E2F7, another cell cycle regulator. Cell function analysis shows that overexpression of miR-29 downregulates the expression of these cell cycle genes, induces partial G1 arrest leading to decreased cell proliferation. Taken together our data suggest that the RMS state is stabilized by the deregulation of multiple miRNAs and their target genes, supporting a tumor suppressor role for these miRNA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330340     DOI: 10.1038/labinvest.2012.10

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  56 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

2.  SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.

Authors:  Davide Martino Coda; Marcello Francesco Lingua; Deborah Morena; Valentina Foglizzo; Francesca Bersani; Ugo Ala; Carola Ponzetto; Riccardo Taulli
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Down-regulation of miR-29c in human bladder cancer and the inhibition of proliferation in T24 cell via PI3K-AKT pathway.

Authors:  Yanru Fan; Xuedong Song; Hongfei Du; Chunli Luo; Xiaorong Wang; Xue Yang; Yin Wang; Xiaohou Wu
Journal:  Med Oncol       Date:  2014-06-22       Impact factor: 3.064

Review 4.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

5.  Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs.

Authors:  Jingmin Shu; Zhilian Xia; Lihua Li; Ellen T Liang; Nicholas Slipek; Dawen Shen; Jasmine Foo; Subbaya Subramanian; Clifford J Steer
Journal:  RNA Biol       Date:  2012-09-20       Impact factor: 4.652

6.  Downregulated miR-621 promotes cell proliferation via targeting CAPRIN1 in hepatocellular carcinoma.

Authors:  Yao Zhang; Wei You; Haoming Zhou; Zhiqiang Chen; Guoyong Han; Xueliang Zuo; Long Zhang; Jindao Wu; Xuehao Wang
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

7.  A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas.

Authors:  Peter Y Yu; Mumtaz Y Balkhi; Katherine J Ladner; Hansjuerg Alder; Lianbo Yu; Xiaokui Mo; William G Kraybill; Denis C Guttridge; O Hans Iwenofu
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

Review 8.  MicroRNAs in the pathobiology of sarcomas.

Authors:  Anne E Sarver; Subbaya Subramanian
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

9.  The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia.

Authors:  J-N Gong; J Yu; H-S Lin; X-H Zhang; X-L Yin; Z Xiao; F Wang; X-S Wang; R Su; C Shen; H-L Zhao; Y-N Ma; J-W Zhang
Journal:  Cell Death Differ       Date:  2013-09-27       Impact factor: 15.828

Review 10.  Mechanisms of impaired differentiation in rhabdomyosarcoma.

Authors:  Charles Keller; Denis C Guttridge
Journal:  FEBS J       Date:  2013-07-31       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.